



16/06/2024

CURRICULUMVITAEETSTUDIORUM

GIOVANNI PONTI, M.D., Ph.D

EDUCATION

1998 Medical Degree, 110/110 cum laude, University of Naples

2002 Residency in Gastroenterology, University of Naples

From 2021 Associate Professor, Clinical pathology, University of Modena and Reggio Emilia

ACADEMIC AND RESEARCH EXPERIENCE

2006 PhD in Clinical and Experimental Oncology, University of Modena and Reggio Emilia 2006-

2007 ESO (European School of Oncology) Fellowship at the Oncology Institute of Southern Switzerland, Bellinzona (Switzerland).

FIELD OF RESEARCH

His primary research goals are directed toward understanding the clinical and genetic background of the hereditary cancer syndromes, the cancer genetics, the prevention of neoplastic diseases and their targeted therapy. He is involved in ongoing clinical trials and studies evaluating new oncologic treatments based on experimental targeted-therapies and in research projects regarding cells cultures obtained by both healthy and gene-carriers patients. His main areas of interest are the molecular mechanisms and genetics of hereditary cancer syndromes and rare tumors, which have been the focus of his medical research over the past decade.

Dr Ponti is the primary author of over 40 peer reviewed scientific articles and more than 60 abstracts. He has been an invited speaker at numerous national and international scientific meetings. He has served as a reviewer for several Oncology and Pathology journals (Int J Cancer, J Cut Patho, Int J Derm) and has organized scientific meetings and refresher courses.

Research activities:

- 1) Riegler G, Savastano A, Selvaggi F, Ciociano R, Martino R, Riccio G, Iorio R, **Ponti G**, Carratù R, et al. *Prevalence of HNPCC in a series of consecutive patients on the first endoscopic diagnosis of colorectal cancer: a multi-Centre Study* Endoscopy 1999; 31 (5): 337-341). **IF:6.096; Cit. 10**
- 2) Ponz de Leon M, Benatti P, Borghi F, Pedroni M, Scarselli A, Di Gregorio C, Losi L, Viel A, Genuardi M, Abbati G, Rossi G, Menigatti M, Lamberti I, **Ponti G**, Roncucci L. *Aetiology of colorectal cancer and relevance of monogenic inheritance*. Gut 2004 Jan; 53 (1):115-22. ISSN: 0017-5749, doi: 10.1136/gut.53.1.115 **IF:10.614; Cit. 16**
- 3) Ponz de Leon M, Marino M, Benatti P, Rossi G, Menigatti M, Pedroni M, Di Gregorio C, Losi L, Borghi F, Scarselli A, **Ponti G**, Roncari B, Zangardi G, Abbati G, Ascari E, Roncucci L. *Trend of incidence, subsite distribution and staging of colorectal neoplasm in the 15-year experience of a specialised cancer registry*. Ann Oncol. 2004 Jun; 15 (6):940-6. ISSN: 0923-7534, doi: 10.1093/annonc/mdh224 **IF: 6.452; Cit. 51**
- 4) Ponz de Leon M, Benatti P, Di Gregorio C, Pedroni M, Losi L, Genuardi M, Viel A, Fornasari M, Lucci-Cordisco E, Anti M, **Ponti G**, Borghi F, Lamberti I, Roncucci L. *Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer*. British Journal of Cancer; 2004 Feb. 23;90 (4):882-7. ISSN: 0007-0920, doi: 10.1038/sj.bjc.6601529 **IF: 4.831; Cit.55**
- 5) Losi L, Scarselli A, Benatti P, Ponz de Leon M, Roncucci L, Pedroni M, Borghi F, Lamberti I, Rossi G, Marino M, **Ponti G**, Zangardi G, Menigatti M, Di Gregorio C. *Relationship between MUC5AC and altered expression of MLH1 protein in mucinous and non-mucinous colorectal carcinomas*. Pathol Res Pract. 2004; 200 (5): 371-7. ISSN: 0344-0338, doi: 10.1016/j.prp.2004.01.008 **IF: 1.258; Cit.20**
- 6) Di Gregorio C, Benatti P, Losi L, Roncucci L, Rossi G, **Ponti G**, Marino M, Pedroni M, Scarselli A, Roncari B, Ponz de Leon M. *Incidence and survival of patients with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study*. Int J Colorectal Dis.2005 Mar ;20:147-54. ISSN: 0179-1958, doi: 10.1007/s00384-004-0665-6 **IF:2.1; Cit.18**
- 7) **Ponti G**, Losi L, Di Gregorio C, Roncucci L, Pedroni M, Scarselli A, Benatti P, Seidenari S, Pellacani G, Lembo L, Rossi G, Marino M, Lucci-Cordisco E, Ponz de Leon M. *Identification of Muir-Torre Syndrome among patient with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability and immunohistochemistry*. Cancer 2005 ; Mar 1; 103 (5):1018-25. ISSN: 0008-543X, doi: 10.1002/cncr.20873 **IF:5; Cit. 83**
- 8) **Ponti G**, Ponz de Leon M, Losi L, Di Gregorio C, Benatti P, Pedroni M, Scarselli A, Riegler G, Lembo L, Pellacani G, Seidenari S, Rossi G, Roncucci L. *Different Phenotypes in Muir-Torre*

- sindrome: clinical and biomolecular characterization in two italian families. British Journal of dermatology.* Br J Dermatol. 2005 Jun; 152(6): 1335-8. ISSN: 0007-0963, doi: 10.1111/j.1365-2133.2005.06506.x **IF: 4; Cit. 23**
- 9) **Ponti G**, Ponz de Leon M, Maffei S, Pedroni M, Losi L, Di Gregorio C, Gismondi V, Scarselli A, Benatti P, Roncari B, Seidenari S, Pellacani G, Varotti C, Varesco L, Roncucci L. *Attenuated Familial Polyposis and Muir-Torre Syndrome linked to compound biallelic constitutional MYH gene mutations.* Clinical Genetics 2005 Nov; 68 (5): 442-7. ISSN: 0009-9163, doi: 10.1111/j.1399-0004.2005.00519.x **IF: 2.943; Cit. 53**
- 10) Losi L, Di Gregorio C, Pedroni M, **Ponti G**, Roncucci L, Scarselli A, Genuardi M, Baglioni S, Marino M, Rossi G, Benatti P, Maffei S, Menigatti M, Roncari B, Ponz de Leon M. *Molecular genetic alterations and clinical features in early onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes.* American Journal of Gastroenterology 2005 Oct; 100(10): 2280-7. ISSN: 0002-9270, doi: 10.1111/j.1572-0241.2005.00223.x **IF: 7; Cit. 38**
- 11) Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, **Ponti G**, Santini A, Losi L, Di Gregorio C, Oliani C, Ponz de Leon M, Lanza G. *Micosatellite instability and colorectal cancer prognosis.* Clinical Cancer Research 2005; Dec 11: 8332-40. ISSN: 1078-0432, doi: 10.1158/1078-0432.CCR-05-1030 **IF: 6.75; Cit.189**
- 12) **Ponti G**, Ponz de Leon M. *Muir-Torre Syndrome.* The Lancet Oncology 2005; December 6 (12): 980-987. doi: 10.1016/S1470-2045(05)70465-4 **IF:18; Cit.152**
- 13) Losi L, **Ponti G**, Di Gregorio C, Marino M, Rossi G, Pedroni M, Benatti P, Roncucci L, Ponz de Leon M. *Prognostic significance of histologic features and biologic parameters in stage I (pT1 and pT2) colorectal adenocarcinoma.* Pathol Res Pract. 2006;202(9):663-70. ISSN: 0344-0338, doi: 10.1016/j.prp.2006.05.003 **IF: 1,25; Cit. 34**
- 14) Di Gregorio C, Frattini M, Maffei S, **Ponti G**, Losi L, Pedroni M, Venesio T, Bertario L, Risio M, Ponz de Leon M. *Immunohistochemistry expression of MYH protein can be used to identify patients with MYH-Associated polyposis.* Gastroenterology. 2006 Aug;131(2):439-44. ISSN: 0016-5085, doi: 10.1053/j.gastro.2006.05.049 **IF: 7; Cit.21**
- 15) **Ponti G**, Losi L., Pedroni M, Lucci-Cordisco E, Di Gregorio C, Pellacani G, Seidenari S. *Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre Syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.* J Invest Dermatol. 2006 Oct;126(10):2302-7. ISSN: 0022-202X, doi: 10.1038/sj.jid.5700475 **IF: 6.25; Cit. 71**
- 16) **Ponti G**, Venesio T, Losi L, Pellacani G, Bertario L, Sala L, Pedroni M., Petti C, Maffei S,

- Varesco L, Baggio A, Sedenari S. "BRAF mutations in multiple sebaceous hyperplasias of patients belonging to MYH-associated polyposis pedigrees" J Invest Dermatol. 2006 (Accepted, 15 Nov 2006) ISSN: 0022-202X, doi: 10.1038/sj.jid.5700723 **IF: 6.25; Cit.11**
- 17) Roncari B, Pedroni M, Maffei S, Di Gregorio C, **Ponti G**, Scarselli A, Losi L, Benatti P, Roncucci L, DGaetani C, Camellini L, Lucci-Cordiso E, Tricarico R, Genuardi M, Ponz de Leon M. *Frequency of constitutional MSH6 mutations in a consecutive series of families with clinical suspicion of HNPCC*. Clin Genet 2007 Sep;72(3):230-7 ISSN: 0009-9163, doi: 10.1111/j.1399-0004.2007.00856.x **IF: 2.942; Cit.11**
- 18) Pedroni M, Roncari B, Maffei S, Losi L, Scarselli A, Di Gregorio C, Marino M, Roncucci L, Benatti P, **Ponti G**, Rossi G, Menigatti M, Viel A, Genuardi M, MP de Leon. *A mononucleotide markers panel to identify hMLH1/hMSH2 germline mutations*. Dis Markers. 2007;23(3):179-87. ISSN: 0278-0240, doi: 10.1155/2007/703129 **IF:2.03; Cit.20**
- 19) de Leon MP, Benatti P, Di Gregorio C, Losi L, Pedroni M, **Ponti G**, Genuardi M, Viel A, LucciCordisco E, Rossi G, Roncucci L. *Genotype-phenotype correlations in individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer*. Scand J Gastroenterol. 2007 Jun; 42(6):746-53. doi: 10.1080/00365520601026681 ISSN: 0036-5521 **IF: 1.5; Cit.8**
- 20) Ponz de Leon M, Rossi G, di Gregorio C, De Gaetani C, Rossi F, **Ponti G**, PeconeL, Pedroni M, Roncucci L, Pezzi A, Benatti P. *Epidemiology of colorectal cancer: the 21-year experience of a specialised registry*. Intern Emerg Med. 2007 Nov 29. ISSN: 1828-0447, doi: 10.1007/s11739-0070077-z **IF: 2.3; Cit.28**
- 21) **Ponti G**, Losi L, Pellacani G, Rossi G.B., Presutti L, Mattioli F, Villari D, Izzo P, De Rosa M, Marone P, Seidenari S. *Wnt pathway, angiogenetic and hormonal markers in Sporadic and Familial Adenomatous Polyposis associated Juvenile Nasopharyngeal Angiofibromas (JNA)*. Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):173-8. ISSN: 1541-2016, doi: 10.1097/PAI.0b013e31806bee12 **IF: 1.5; Cit.16**
- 22) **Ponti G**, Ponzoni M, Andrès JMF., Foppoli M, Mazzucchelli L, Zucca E. *The impact of histopathologic diagnosis on the proper management of testis neoplasms*. Nat Clin Pract Oncol. 2008 Oct; 5 :619-22. ISSN: 1743-4254, doi: 10.1038/ncponc1218 **IF:10,78; Cit.2**
- 23) **Ponti G**, Losi L, Pellacani G., Wannesson L., Cesinaro AM, Venesio T, Petti C, Seidenari S. et al. *Malignant melanoma in Hereditary Non-Polyposis Colorectal Cancer Hereditary Non Polyposis Colorectal Cancer (HNPCC) patients*. Br J Dermatol. 2008 Jul;159: 162-8. ISSN: 0007-0963, doi: 10.1111/j.1365-2133.2008.08575.x **IF: 4.35; Cit.13**

- 24) Domati F, Travlos E, Cirilli C, Rossi G, Benatti P, Marino M, **Ponti G**, Vandelli M, Valmori S, Oursana A, Pezzi A, Ponz de Leon M. *Attitude of the Italian general population towards prevention and screening of the most common tumors, with special emphasis on colorectal malignancies*. Intern Emerg Med 2008 Sep 20. ISSN: 1828-0447, doi: 10.1007/s11739-008-0184-5 **IF: 2.3; Cit.7**
- 25) AIRTUM Working Group, Crocetti E, Buzzoni C. *New incidence and mortality data. 2003-2005*. Epidemiol Prev. 2009 Apr 23;33. ISSN: 1120-9763
- 26) Mattioli F, Masoni F, **Ponti G**, Rossi G, Molteni G, Alicandri-Ciufelli M, Presutti L. *"Collision" metastasis from unknown primary squamous cell carcinoma and papillary microcarcinoma of thyroid presenting as lateral cervical cystic mass*. Auris Nasus Larynx. 2009 Jun;36(3):372-5. Epub 2008 Jul 10. ISSN: 0385-8146, doi: 10.1016/j.anl.2008.04.015 **IF: 0.6; Cit.6**
- 27) Malavasi N, **Ponti G**, Bertolini F, Depenni R, Zironi S, Luppi G, Conte PF. *Complete pathological response in patient affected by liver metastases of colon cancer treated with FOLFOX6 chemotherapy and Bevacizumab*. Journal of Hematology & Oncology 2009 Aug 6;2:35. ISSN: 1756-8722, doi: 10.1186/1756-8722-2-35 **IF: 2.93; Cit.8**
- 28) **Ponti G**, Luppi G, Martorana D, Rossi G, Bertolini F, Sartori G, Losi L, Pellacani G, Seidenari S, Boni E, Neri T M, Silini E, Tamburini E, Maiorana A, Conte PF. *Gastrointestinal stromal tumor (GIST) and other primary metachronous or synchronous neoplasms as suspicion criterion for syndromic setting*. Oncol Rep. 2010 Feb;23(2):437-44. ISSN: 1021-335X, doi: 10.3892/or_00000653 **IF: 1.686; Cit.25**
- 29) **Ponti G**, Luppi G, Losi L, Giannetti A, Seidenari S. *Leser-Trelat syndrome in patients affected by six multiple metachronous primitive cancer*. Journal of Hematology & Oncology 2010 Jan 11;3(1):2. ISSN: 1756-8722, doi: 10.1186/1756-8722-3-2 **IF: 2.3; Cit.15**
- 30) **Ponti G**, Luppi G, Giacobbi F, Corradini G, Temperani P, Losi L, Ferrara L, Pagano M, Seidenari S, Tagliafico E, Torelli G, Conte PF. *Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies*. Cancer Genetic and Cytogenetic 2010; 200:1-7. ISSN: 0165-4608, doi: 10.1016/j.cancergencyto.2009.10.006 **IF:1.54; Cit.3**
- 31) Seidenari S., Ferrari C, Borsari S., Benati E, **Ponti G**, Bassoli S, Giusti F, Schianchi S, Pellacani G. *Reticular grey-blue areas of regression as a dermoscopic marker of melanoma in situ*. British J of Derm 2010; 163:302-309. ISSN: 0007-0963, doi: 10.1111/j.1365-2133.2010.09821.x **IF: 4; Cit.20**
- 32) **Ponti G**, Losi L, Pellacani G, Cesinaro A, Boni E, Pepe P, Landi MT, Luppi G, Conte PF, Seidenari S. *p16 immunohistochemistry of multiple primary melanomas as screening to identify*

Familial Melanoma Syndrome. Inter J of Dermatology. 2012 Apr;51(4):488-92. ISSN: 0011-9059
DOI: 10.1111/j.1365-4632.2010.04496.x **IF: 1.342; Cit.2**

33) Bassoli S, Borsari S, Ferrari C, Giusti F, Pellacani G, **Ponti G**, Seidenari S. *is ready: Grey-blue regression in melanoma in situ evaluation on 111 cases*. Journal of Skin Cancer 2011, 2011:180980.

ISSN: 2090-2905, doi: 10.1155/2011/180980

34) **Ponti G**, Losi L, Martorana D, Priola M, Boni E, Pollio A, Neri TM, Seidenari S. *Clinicopathological and biomolecular findings in Italian patients with multiple cutaneous neurofibromas*. Hereditary Cancer in Clinical Practice 2011,12 9:6. ISSN: 1731-2302, doi: 10.1186/1897-4287-9-6

IF:0.28; Cit.7

35) **Ponti G**, Nasti S, Losi I, Pastorino L, Pollio A, Benassi L, Giudice S, Bertazzoni G, Veratti E, Azzoni P, Bianchi Scarrà G, Seidenari S. *Broke-Spiegler Syndrome: report of two cases not associated with a mutation in the CYLD and PTCH tumor suppressor genes*. Journal of Cutaneous Pathology. Nov 12 2011. ISSN: 0303-6987, doi: 10.1111/j.1600-0560.2011.01813.x

IF:1.74; Cit.2

36) Benati E, Bellini V, Borsari S, Dunsby C, Ferrari C, French P, Guanti M, Guardoli D, Koenig K, Pellacani G, **Ponti G**, Schianchi S, Talbot C, Seidenari S. *Quantitative evaluation of healthy epidermis by means of multiphoton microscopy and fluorescence lifetime imaging microscopy*. Skin Res Technol. 2011 Apr 25. ISSN: 1600-0846, doi: 10.1111/j.1600-0846.2011.00496.x

IF:1.59; Cit.27

37) Seidenari S, Benati E, **Ponti G** et al., *Italian Euromelanoma Day Screening Campaign (2005–2007) and the planning of melanoma screening strategies*. Eur J Cancer Prev. 2012 Jan;21(1):89-95.

ISSN: 0959-8278, doi: 10.1097/CEJ.0b013e3283498e14 **IF.2.53; Cit.5**

38) **Ponti G**, Pollio A, Pastorino L, Pellacani G, Magnoni C, Nasti S, Fortuna G, Bianchi Scarrà G, Seidenari S. *Patched homolog 1 gene mutation (p.G1093R) induces nevoid basal cell carcinoma syndrome and non-syndromic keratocystic odontogenic tumors: A case report*. Oncol Lett. 2012 Aug;4(2):241-244. Epub 2012 May 8. ISSN: 1792-1082, doi: 10.3892/ol.2012.707 **IF: 0.237; Cit.4**

39) **Ponti G**, Pollio A, Cesinaro AM, Magnoni C, Seidenari S. *Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients*. Cancer

Epidemiology Dec 5 2011. ISSN: 1877-7821, doi: 10.1016/j.canep.2011.11.003 **IF:1.18; Cit.2**

40) Seidenari S, Ferrari F, Borsari S, Bassoli S, Cesinaro A, Giusti F, Pellacani G, **Ponti G**, Zalaudek I, Argenziano G. *The dermoscopic variability of pigment in melanoma in situ*. Melanoma

Research 2012 Apr;22(2):151-7. ISSN: 0007-0963, doi: 10.1111/j.1365-2133.2010.09821.x **IF: 3; Cit.9**

41) Seidenari S, Arginelli A, Dunsby C, French P, Guanti M, Guardoli D, König K, Magnoni C, **Ponti G**, Talbot C, Dursly C. *Multiphoton laser tomography and fluorescence lifetime imaging of basal cell carcinoma: Morphologic Features for Non-Invasive Diagnostics*. Exp Dermatol. 2012 Nov;21(11):831-6. doi: 10.1111/j.1600-0625.2012.01554.x **IF: 3.762; Cit.15**

42) **Ponti G**, Pollio A, Mignogna M, Pastorino L, Pellacani G, Bianchi-Scarrà G, Magnini C, Greco M, Seidenari S. *Unicystic ameloblastoma associated to NBCC (Gorlin) Syndrome*. Cancer Genetics. 2012 Apr;205(4):177-81. ISSN: 2210-7762, doi: 10.1016/j.cancergen.2012.01.012 **IF: 1.55; Cit.5**

43) **Ponti G**, Pastorino L, Pollio A, Nasti S, Pellacani G, Mignogna M.D., Del Forno C, Bianchi-Scarrà G, Ficarra G, Seidenari S. *Ameloblastoma as criterion for Nevoid Basal Cell Carcinoma (Gorlin) Syndrome identification*. JID. 2012 Sep;11(3):411-8 ISSN: 1389-9600, doi: 10.1007/s10689-012-9529-3 **IF: 6.27; Cit.11**

44) **Ponti G**, Pollio A, Cesinaro AM, Pellacani G, Magnoni C, Seidenari S. *Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients*. Cancer Epidemiol. 2012 Jun;36(3):303-5. ISSN: 1877-7821, doi: 10.1016/j.canep.2011.11.003 **IF: 1.18; Cit. 2**

45) Seidenari S, Bassoli S, Borsari S, Ferrari C, Giusti F, **Ponti G**, Tomasini C, Magnoni C. *Variegated dermoscopy of in situ melanoma*. Dermatology. 2012;224(3):262-70. **IF: 2.7; Cit.12**

46) Seidenari S, Arginelli F, Bassoli S, Cautela J, Cesinaro AM, Guanti M, Guardoli D, Magnoni C, Manfredini M, **Ponti G**, König K. *Diagnosis of BCC by multiphoton laser tomography*. Skin Res Technol. 2013 Feb;19(1):e297-304. ISSN: 0909-752X, doi: 10.1111/j.1600-0846.2012.00643.x **IF: 1.59; Cit.9**

47) **Ponti G**, Pellacani G, Seidenari S, Pollio A, Muscatello U, Tomasi A. *Cancer-associated genodermatoses: skin neoplasms as clues to hereditary tumor syndromes*. Crit Rev Oncol Hematol. 2013 Mar;85(3):239-56. ISSN: 1040-8428, doi: 10.1016/j.critrevonc.2012.07.001 **IF: 4; Cit.22**

48) **Ponti G**, Pollio A, Tomasi A, Borsari S, Magnoni C, Mandel V.D., Loschi P, Ruini C, Seidenari S. *Are the neck Malignant melanomas different from the ones affecting the head? clinicopathologic, dermoscopic and prognostic findings*. 2013 Head and Neck Oncology, 5 (4), art. no. 44. **IF:3,14; Cit.1**

49) **Ponti G**, Pollio A, Pastorino L, Pellacani G, Magnoni C, Nasti S, Fortuna G, Tomasi A, Scarrà GB, Seidenari S. *Patched homolog 1 gene mutation (p.G1093R) induces nevoid basal cell*

- carcinoma syndrome and non-syndromic keratocystic odontogenic tumors: A case report.* *Oncol Lett.* 2012 Aug;4(2):241-244. ISSN: 1792-1082, doi: 10.3892/ol.2012.707 **IF:0.237; Cit.4**
- 50) Seidenari S, Arginelli F, Dunsby C, French P, König K, Magnoni C, Manfredini M, Talbot C, **Ponti G.** *Multiphoton laser tomography and fluorescence lifetime imaging of basal cell carcinoma: morphologic features for non-invasive diagnostics.* *Exp Dermatol.* 2012 Nov;21(11):831-6. ISSN: 0906-6705, doi: 10.1111/j.1600-0625.2012.01554.x **IF: 3.5; Cit.15**
- 51) Pastorino L, Pollio A, Pellacani G, Guarneri C, Ghiorzo P, Longo C, Bruno W, Giusti F, Bassoli S, Bianchi-Scarrà G, Ruini C, Seidenari S, Tomasi A, **Ponti G.** *Novel PTCH1 mutations in patients with keratocystic odontogenic tumors screened for nevoid basal cell carcinoma (NBCC) syndrome.* *PLoS One.* 2012;7(8):e43827. ISSN: 1932-6203, doi: 10.1371/journal.pone.0043827 **IF: 3.73; Cit.10**
- 52) **Ponti G,** Tomasi A, Pellacani G. *Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.* *J Hematol Oncol.* 2012 Oct 2;5:60. ISSN: 1756-8722, doi: 10.1186/1756-8722-5-60 **IF: 2.93; Cit.13**
- 53) **Ponti G,** Tomasi A, Pastorino L, Ruini C, Guarneri C, Mandel VD, Seidenari S, Pellacani G. *Diagnostic and pathogenetic role of café-au-lait macules in nevoid basal cell carcinoma syndrome.* *Hered Cancer Clin Pract.* 2012 Oct 29;10(1):15. ISSN: 1045-7410, doi: 10.1186/1897-4287-10-15 **IF:0.28; Cit.2**
- 54) Catena F, Di Battista M, Ansaloni L, Pantaleo M, Fusaroli P, Di Scioscio V, Santini D, Nannini M, Saponara M, **Ponti G,** Persiani R, Delrio P, Coccolini F, Di Saverio S, Biasco G, Lazzareschi D, Pinna A. GISTologist Study Group. *Microscopic margins of resection influence primary gastrointestinal stromal tumor survival.* *Onkologie.* 2012;35(11):645-8. ISSN: 0378-584X, doi: 10.1159/000343585 **IF:1;Cit.3**
- 55) Manfredini M, Arginelli F, Dunsby C, French P, Talbot C, König K, Pellacani G, **Ponti G,** Seidenari S. *High-resolution imaging of basal cell carcinoma: a comparison between multiphoton microscopy with fluorescence lifetime imaging and reflectance confocal microscopy.* *Skin Res Technol.* 2013 Feb;19(1):e433-43. **IF:1.59; Cit. 6**
- 56) Longo C, Farnetani F, Moscarella E, de Pace B, Ciardo S, **Ponti G,** Piana S, Cesinaro AM, Cota C, Argenziano G, Rosendahl C, Pellacani G, Zalaudek I. *Can noninvasive imaging tools potentially predict the risk of ulceration in invasive melanomas showing blue and black colors?* *Melanoma Res.* 2013 Apr;23(2):125-31. **IF: 3; Cit.8**
- 57) Lo Muzio L, Pastorino L, Levanat S, Musani V, Situm M, **Ponti G,** Bianchi Scarra G. *Clinical utility gene card for: Gorlin syndrome-update 2013.* *Eur J Hum Genet.* 2013 Oct;21(10). ISSN: 1018-

4813, doi: 10.1038/ejhg.2012.299 **IF: 4.225; Cit.1**

58) Longo C, Farnetani F, Ciardo S, Cesinaro AM, Moscarella E, **Ponti G**, Zalaudek I, Argenziano G, Pellacani G. *Is confocal microscopy a valuable tool in diagnosing nodular lesions? A study of 140 cases.* Br J Dermatol. 2013 Jul;169(1):58-67. **IF: 4; Cit.22**

59) **Ponti G**, Longo C. *Microsatellite instability and mismatch repair protein expression in sebaceous tumors, keratocanthoma, and basal cell carcinomas with sebaceous differentiation in Muir-Torre syndrome.* J Am Acad Dermatol. 2013 Mar;68(3):509-10. **IF: 5.004; Cit.3**

60) **Ponti G**, Pellacani G, Tomasi A, Gelsomino F, Spallanzani A, Depenni R, Al Jalbout S, Simi L, Garagnani L, Borsari S, Conti A, Ruini C, Fontana A, Luppi G. *The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.* J Clin Pathol. 2013 May;66(5):441-5. **IF: 2.551; Cit. 13**

61) Magnoni C, Giudice S, Pellacani G, Bertazzoni G, Longo C, Veratti E, Morini D, Benassi L, Vaschieri C, Azzoni P, De Pol A, Seidenari S, Tomasi A, Pollio A, **Ponti G**. *Stem cell properties in cell cultures from different stage of melanoma progression.* Appl Immunohistochem Mol Morphol. 2014 Mar;22(3):171-81. **IF: 2.012; Cit.6**

62) Pollio A, Tomasi A, Seidenari S, Pellacani G, Rodolfo M, Frigerio S, Maurichi A, Turchetti D, Bassoli S, Ruini C, **Ponti G**. *Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of MITF, PTEN and CDKN2A in multiple cancerogenesis?* Pigment Cell Melanoma Res. 2013 Sep;26(5):755-7. ISSN: 1755-1471, doi: 10.1111/pcmr.12122 **IF: 5.641; Cit.0**

63) Seidenari S, Ferrari C, Borsari S, Fabiano A, Bassoli S, Giusti F, **Ponti G**, Magnoni C. *Dermoscopy of small melanomas: just miniaturized dermoscopy?* Br J Dermatol. 2014 Nov;171(5):1006-13. **IF: 4.28; Cit.3**

64) Seidenari S, Arginelli F, Dunsby C, French PM, König K, Magnoni C, Talbot C, **Ponti G**. *Multiphoton laser tomography and fluorescence lifetime imaging of melanoma: morphologic features and quantitative data for sensitive and specific non-invasive diagnostics.* PLoS One. 2013 Jul

26;8(7):e70682. **IF: 3.534; Cit.11**

65) **Ponti G**, Ruini C, Massi D, Pellacani G, Tomasi A, Paglierani M, Loschi P, Seidenari S. *Fluorescence in-situ hybridization and dermoscopy in the assessment of controversial melanocytic tumors.* Melanoma Res. 2013 Dec;23(6):474-80. **IF: 3; Cit.1**

66) **Ponti G**, Bertazzoni G, Pastorino L, Monari E, Cuoghi A, Bergamini S, Bellei E, Benassi L, Azzoni P, Petrachi T, Magnoni C, Pellacani G, Loschi P, Pollio A, Witkowski AM, Tomasi A. *Proteomic analysis of PTCH1+/- fibroblast lysate and conditioned culture media isolated from the*

- skin of healthy subjects and nevoid basal cell carcinoma syndrome patients.* Biomed Res Int. 2013;2013:794028. ISSN: 1110-7251, doi: 10.1155/2013/794028 **IF: 2.706; Cit.1**
- 67) Seidenari S, Pellacani G, Nasti S, Tomasi A, Pastorino L, Ghiorzo P, Ruini C, Bianchi-Scarrà G, Pollio A, Mandel VD, **Ponti G.** *Hereditary trichilemmal cysts: a proposal for the assessment of diagnostic clinical criteria.* Clin Genet. 2013 Jul;84(1):65-9. **IF: 3.652; Cit. 1**
- 68) **Ponti G,** Ruini C, Girolomoni G, Pellacani G, Farnetani F, Pastorino L, Ghiorzo P, Witkowski AM, Bianchi-Scarrà G, Tomasi A, Loschi P, Nasti S. *Brooke-Spiegler syndrome tumor spectrum beyond the skin: a patient carrying germline R936X CYLD mutation and a somatic CYLD mutation in Brenner tumor.* Future Oncol. 2014 Feb;10(3):345-50. **IF: 2.477; Cit. 2**
- 69) **Ponti G,** Tomasi A. *Giuseppe Moscati (1880-1927): a holistic approach to medicine.* J Med Biogr. 2013 Sep 16;22(2):80-82. **IF:0; Cit.1**
- 70) **Ponti G,** Pellacani G, Tomasi A, Loschi P, Luppi G, Gelsomino F, Longo C. *Molecular targeted approaches for advanced BRAF V600, N-RAS, c-KIT, and GNAQ melanomas.* Dis Markers. 2014;2014:671283. **IF: 1.562; Cit.6**
- 71) Pollio A, Tomasi A, Pellacani G, Ruini C, Mandel VD, Fortuna G, Seidenari S, **Ponti G.** *Multiple primary melanomas versus single melanoma of the head and neck: a comparison of genetic, diagnostic, and therapeutic implications.* Melanoma Res. 2014 Jun;24(3):267-72. **IF:3; Cit.1** 72) Seidenari S, Bellucci C, Bassoli S, Arginelli F, Magnoni C, **Ponti G.** *High magnification digital dermoscopy of basal cell carcinoma: a single-centre study on 400 cases.* Acta Derm Venereol. 2014 Nov;94(6):677-82. **IF:4.244; Cit.1**
- 73) **Ponti G,** Martorana D, Pellacani G, Ruini C, Loschi P, Baccarani A, De Santis G, Pollio A, Neri TM, Mandel VD, Maiorana A, Maccio L, Maccaferri M, Tomasi A. *NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies.* Anticancer Res. 2014 Jun;34(6):3021-30. **IF:1.826; Cit.2**
- 74) **Ponti G,** Ruini C, Pastorino L, Loschi P, Pecchi A, Malagoli M, Mandel VD, Boano R, Conti A, Pellacani G, Tomasi A. *Skeletal and cranio-facial signs in Gorlin syndrome from ancient Egypt to the modern age: sphenoid asymmetry in a patient with a novel PTCH1 mutation.* Future Oncol. 2014 May;10(6):917-25. **IF:2.477**
- 75) **Ponti G,** Pellacani G, Ruini C, Percesepe A, Longo C, Mandel VD, Crucianelli F, Gorelli G, Tomasi A. *Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.* Fam Cancer. 2014 Dec;13(4):553-61. **IF:1.977; Cit. 2**

- 76) Guardoli D, Argenziano G, **Ponti G**, Nasti S, Zalaudek I, Moscarella E, Lallas A, Piana S, Specchio F, Martinuzzi C, Raucci M, Pellacani G, Longo C. *A novel CYLD germline mutation in Brooke-Spiegler syndrome*. J Eur Acad Dermatol Venereol. 2014 Jul 30. **IF:3.105; Cit. 2**
- 77) **Ponti G**, Meschieri A, Pollio A, Ruini C, Manfredini M, Longo C, Mandel VD, Ciardo S, Tomasi A, Giannetti L, Pellacani G. *Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy*. J Oral Pathol Med. 2014 Sep 12. **IF:1.926; Cit.1**
- 78) **Ponti G**, Pellacani G, Tomasi A, Percesepe A, Guarneri C, Guerra A, Mandel VD, Kisla E, Cevikel P, Neri C, Menozzi C, Seidenari S. *Hypomelanosis of Ito with a trisomy 2 mosaicism: a case report*. J Med Case Rep. 2014 Oct 9;8:333. ISSN: 1752-1947, doi: 10.1186/1752-1947-8-333 **IF:0.4; Cit.0**
- 79) **Ponti G**, Manfredini M, Tomasi A, Pellacani G. *Distinctive clinical and dermoscopic features of BRAFp.V600K mutated melanomas*. Br J Dermatol. 2015 May;172(5):1438-40. ISSN: 0007-0963, doi: 10.1111/bjd.13484 **IF:4.1**
- 80) **Ponti G**, Castellsagué E, Ruini C, Percesepe A, Tomasi A. *Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome*. Clin Genet. 2015 Jun;87(6):507-16. ISSN: 0009-9163, doi: 10.1111/cge.12529 **IF:3.931; Cit. 3**
- 81) **Ponti G**, Ruini C, Tomasi A. *Mismatch repair gene deficiency and genetic anticipation in lynch syndrome: myth or reality?* Dis Colon Rectum. 2015 Jan;58(1):141-2. ISSN: 0012-3706, doi: 10.1097/DCR.0000000000000275 **IF:3.749 Cit.3**
- 82) **Ponti G**, Manfredini M, Tomasi A, Pellacani G. *“Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge”*. Gene. 2015 Jul 2. pii: S0378-1119(15)00802-1. ISSN: 0378-1119, doi: 10.1016/j.gene.2015.06.078 **IF: 2.138**
- 83) Ruini C, Manfredini M, Pellacani G, Mandel VD, Tomasi A, **Ponti G**. *“Confocal microscopy characterization of BRAFV600E mutated melanomas”*. Melanoma Res. 2015 Aug;25(4):367-71. ISSN: 0960-8931, doi: 10.1097/CMR.0000000000000147 **IF:2.098**
- 84) **Ponti G**, D' Onofrio F, Ruini C, Muscatello U, Tomasi A. *“Giuseppe Moscati: a man, a physician and a scientist”*. Acta Med Hist Adriat. 2015;13(1):171-80. ISSN: 1334-4366 **IF:0**
- 85) Farnetani F, Manfredini M, Mandel VD, **Ponti G**. *Giuseppe Mariani: the Biography on the fiftieth anniversary of his death*. G Ital Dermatol Venereol. 2015 Oct;150(5):638-9. **IF: 0.677**
- 86) Farnetani F, Manfredini M, Mandel VD, **Ponti G**. *Leonardo Martinotti: the biography on the fiftieth anniversary of his death*. G Ital Dermatol Venereol. 2015 Dec;150(6):768-9. No abstract available. ISSN: 1827-1820 **IF: 0.677**
- 87) **Ponti G**, Tomasi A, Maiorana A, Ruini C, Maccaferri M, Cesinaro AM, Depenni R, Manni P,

- Gelsomino F, Giusti F, Garagnani L, Pellacani G. “*BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?*” Appl Immunohistochem Mol Morphol. 2016 Jan;24(1):30-4. ISSN: 1541-2016, doi: 10.1097/PAI.0000000000000153 **IF:2.012**
- 88) **Ponti G**, Pellacani G, Tomasi A, Sammaria G, Manfredini M. “*Skeletal stigmata as keys to access to the composite and ancient Gorlin-Goltz syndrome history: The Egypt, Pompeii and Herculaneum lessons*”. Gene. 2016vol. 589 (2), p. 104-111 ISSN: 0378-1119, doi: 10.1016/j.gene.2016.01.012 **IF: 2.138**
- 89) **Ponti G**, Tomasi A, Manfredini M, Pellacani G. “*Oral mucosal stigmata in hereditary-cancer syndromes: From germline mutations to distinctive clinical phenotypes and tailored therapies*”. Gene. 2016 May 10;582(1):23-32. ISSN: 0378-1119, doi: 10.1016/j.gene.2016.01.053 **IF: 2.138; Cit.3**
- 90) Mandel Victor Desmond, Persechino Flavia, Berardi Alberto, Ponti Giovanni, Ciardo Silvana, Rossi Cecilia, Pellacani Giovanni, Farnetani Francesca (2016). *Congenital Glioblastoma multiforme and eruptive disseminated Spitz nevi*. THE ITALIAN JOURNAL OF PEDIATRICS, vol. 42, p. 47-52, ISSN: 1720-8424, doi: 10.1186/s13052-016-0260-9
- 91) Longo C, Pellacani G, Tomasi A, Mandel VD, **Ponti G**. “*Fibroepithelioma of Pinkus: Solitary tumor or sign of a complex gastrointestinal syndrome*. Molecular and Clinical Oncology. 2016 vol. 4(5), p. 797-800, ISSN: 2049-9450, doi: 10.3892/mco.2016.794
- 92) **Ponti G**, Pellacani G, Martorana D, Mandel VD, Loschi P, Pollio A, Pecchi A, Dealis C, Seidenari S, Tomasi A. “*Giant elephantiasis neuromatosa in the setting of neurofibromatosis type 1: a case report*”. Oncology Letters, vol. 11, p. 3709-3714 2016 ISSN: 1792-1074, doi: 10.3892/ol.2016.4469 **IF:1.554**
- 93) **Ponti G**, Manfredini M, Pellacani G, Tomasi A. “*Role of microsatellite instability, immunohistochemistry and Mismatch Repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre Syndrome*”. Clin Chem Lab Med. 2016 In press. doi: 10.1515/cclm-2015-1210 **IF:2.707**
- 94) **Ponti Giovanni**, Pellacani Giovanni, Sestini Roberta, Gorelli Greta, Tomasi Aldo (2016). *Microsatellite instability, immunohistochemistry and germline mismatch repair gene mutations for the diagnosis of Muir-Torre syndrome in immunosuppressed patients*. BIOCHIMICA CLINICA, vol. 40, p. 108-112, ISSN: 0393-0564, doi: 10.19186/BC_2016.009
- 95) **Ponti G**. and Muscatello U. “*The long road to the use of microscope in clinical medicine in vivo: from early pioneering proposals to the modern perspectives of optical biopsy*”. Acta Medico-

Historico Adriatica; 2015;13(2):385-92. ISSN: 13344366

- 96) Manfredini M, Pellacani G, Losi L, Maccaferri M, Tomasi A, **Ponti G**. *Desmoplastic melanoma: a challenge for the oncologist*. Future Oncol. 2017 Feb;13(4):337-345. ISSN: 1479-6694, doi: 10.2217/fon-2016-0334
- 97) **Ponti G**, Manfredini M, Greco S, Pellacani G, Depenni R, Tomasi A, Maccaferri M, Cascinu S. *BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival*. Anticancer Res. 2017 Dec;37(12):7043-7048.
- 98) **Ponti G**, Manfredini M, Pastorino L, Maccaferri M, Tomasi A, Pellacani G. *PTCH1 Germline Mutations and the Basaloid Follicular Hamartoma Values in the Tumor Spectrum of Basal Cell Carcinoma Syndrome (NBCCS)*. Anticancer Res. 2018 Jan;38(1):471-476.
- 99) Colaci M, **Ponti G**. *Innovative use of magnesium oxide in the treatment of "neuralgia of the celiac plexus of rheumatic origin" by G. Moscati in 1923*. Acta Med Hist Adriat. 2018 Jun;16(1):157-166.
- 100) **Ponti G**, Maccaferri M, Micali S, Manfredini M, Milandri R, Bianchi G, Pellacani G, Kaleci S, Chester J, Conti A, Del Prete C, Tomasi A. *Seminal Cell Free DNA Concentration Levels Discriminate Between Prostate Cancer and Benign Prostatic Hyperplasia*. Anticancer Res. 2018 Sep;38(9):5121-5125
- 100) Depenni R, De Rosa F, Greco S, Ridolfi L, Pellacani G, **Ponti G**, Cascinu S, Guidoboni M. *Dabrafenib-trametinib combination in 'field-practice': an Italian experience*. Future Oncol. 2018 Aug;14(20):2045-2052. doi: 10.2217/fon-2017-0714. Epub 2018 Aug 7.
- 101) **Ponti G**, Maccaferri M, Mandrioli M, Manfredini M, Micali S, Cotugno M, Bianchi G, Ozben T, Pellacani G, Del Prete C, Tomasi A. *Seminal Cell-Free DNA Assessment as a Novel Prostate Cancer Biomarker*. Pathol Oncol Res. 2018 Oct;24(4):941-945. doi: 10.1007/s12253-018-0416-6. Epub 2018 May 5.
- 102) **Ponti G**, Maccaferri M, Manfredini M, Cotugno M, Pellacani G, Conti A, Micali S, Mandrioli M, Tomasi A. *Seminal cell-free DNA molecular profile as a novel diagnostic and prognostic prostate cancer biomarkers*. Med Hypotheses. 2018 May;114:69. doi: 10.1016/j.mehy.2018.02.034. Epub 2018 Feb 26. **IF:1,365**
- 103) **Ponti G**, Maccaferri M, Manfredini M, Kaleci S, Mandrioli M, Pellacani G, Ozben T, Depenni R, Bianchi G, Pirola GM, Tomasi A. *The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients*. Clin Chim Acta. 2018 Apr;479:14-19. doi: 10.1016/j.cca.2018.01.007. Epub 2018 Jan 6. **IF: 2,615**

- 104) **Ponti G**, Manfredini M, Tomasi A. *Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology*. Crit Rev Oncol Hematol. 2019 Jun 7;141:36-42 **IF:5,83**
- 105) **Ponti G**, Maccaferri M, Manfredini M, et al. *Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis*. Clin Chim Acta. 2019; 497:76-
80. doi:10.1016/j.cca.2019.07.011 **IF:2,615**
- 106) **Ponti G**, Pellacani G, Tomasi A, et al. *Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response*. Mol Clin Oncol. 2020;12(1):3-8. doi:10.3892/mco.2019.1946 **IF:0,63**
- 107) Ciccarese G, Dalmaso B, Bruno W, et al. *Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients*. J Transl Med. 2020;18(1):78. Published 2020
- Feb 13. doi:10.1186/s12967-020-02253-8 **IF:3,24**
- 108) Pastorino L, Andreotti V, Dalmaso B, et al. *Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1*. Cancers (Basel). 2020;12(4):1007. Published 2020 Apr 19. doi:10.3390/cancers12041007 **IF:6,102**
- 109) **Ponti G**, Ruini C, Tomasi A. *Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19 [published online ahead of print, 2020 May 21]*. Med Hypotheses. 2020;143:109859. doi:10.1016/j.mehy.2020.109859 **IF:1,375**
- 110) **Ponti G**, Maccaferri M, Ruini C, Tomasi A, Ozben T. *Biomarkers associated with COVID-19 disease progression [published online ahead of print, 2020 Jun 5]*. Crit Rev Clin Lab Sci. 2020;1-11. doi:10.1080/10408363.2020.1770685 **IF:4,817**
- 111) **Ponti G**, De Angelis C, Ponti R, Pongetti L, Losi L, Sticchi A, Tomasi A, Ozben T. *Hereditary breast and ovarian cancer: from genes to molecular targeted therapies*. Crit Rev Clin Lab Sci. 2023 Dec;60(8):640-650. doi: 10.1080/10408363.2023.2234488. Epub 2023 Jul 16. PMID: 37455374.

16 Giugno 2024

16 giugno 2024

